Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
Elgersma RC, Coumans RG, Huijbregts T, Menge WM, Joosten JA, Spijker HJ, de Groot FM, van der Lee MM, Ubink R, van den Dobbelsteen DJ, Egging DF, Dokter WH, Verheijden GF, Lemmens JM, Timmers CM, Beusker PH. Elgersma RC, et al. Among authors: van den dobbelsteen dj. Mol Pharm. 2015 Jun 1;12(6):1813-35. doi: 10.1021/mp500781a. Epub 2015 Feb 18. Mol Pharm. 2015. PMID: 25635711
Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform.
Dokter W, Ubink R, van der Lee M, van der Vleuten M, van Achterberg T, Jacobs D, Loosveld E, van den Dobbelsteen D, Egging D, Mattaar E, Groothuis P, Beusker P, Coumans R, Elgersma R, Menge W, Joosten J, Spijker H, Huijbregts T, de Groot V, Eppink M, de Roo G, Verheijden G, Timmers M. Dokter W, et al. Mol Cancer Ther. 2014 Nov;13(11):2618-29. doi: 10.1158/1535-7163.MCT-14-0040-T. Epub 2014 Sep 4. Mol Cancer Ther. 2014. PMID: 25189543
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.
van der Lee MM, Groothuis PG, Ubink R, van der Vleuten MA, van Achterberg TA, Loosveld EM, Damming D, Jacobs DC, Rouwette M, Egging DF, van den Dobbelsteen D, Beusker PH, Goedings P, Verheijden GF, Lemmens JM, Timmers M, Dokter WH. van der Lee MM, et al. Mol Cancer Ther. 2015 Mar;14(3):692-703. doi: 10.1158/1535-7163.MCT-14-0881-T. Epub 2015 Jan 14. Mol Cancer Ther. 2015. PMID: 25589493
Evaluation of sugammadex self-association.
Kurkov SV, Messner M, Lucassen M, van den Dobbelsteen DJ, den Engelsman J, Loftsson T. Kurkov SV, et al. Among authors: van den dobbelsteen dj. Int J Pharm. 2011 Jul 15;413(1-2):134-9. doi: 10.1016/j.ijpharm.2011.04.044. Epub 2011 Apr 22. Int J Pharm. 2011. PMID: 21539905
Sugammadex is cleared rapidly and primarily unchanged via renal excretion.
Peeters P, Passier P, Smeets J, Zwiers A, de Zwart M, van de Wetering-Krebbers S, van Iersel M, van Marle S, van den Dobbelsteen D. Peeters P, et al. Biopharm Drug Dispos. 2011 Apr;32(3):159-67. doi: 10.1002/bdd.747. Epub 2011 Mar 1. Biopharm Drug Dispos. 2011. PMID: 21370235
Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non-anaesthetised volunteers.
de Kam PJ, Nolte H, Good S, Yunan M, Williams-Herman DE, Burggraaf J, Kluft C, Adkinson NF, Cullen C, Skov PS, Levy JH, van den Dobbelsteen DJ, van Heumen ELGM, van Meel FCM, Glassner D, Woo T, Min KC, Peeters PAM. de Kam PJ, et al. Among authors: van den dobbelsteen dj. Br J Anaesth. 2018 Oct;121(4):758-767. doi: 10.1016/j.bja.2018.05.057. Epub 2018 Jul 13. Br J Anaesth. 2018. PMID: 30236238 Free article. Clinical Trial.
Drug-induced protoporphyria in beagle dogs.
Greijdanus-van der Putten SW, van Esch E, Kamerman J, Ballering LA, van den Dobbelsteen DJ, T de Rijk EP. Greijdanus-van der Putten SW, et al. Among authors: van den dobbelsteen dj. Toxicol Pathol. 2005;33(6):720-5. doi: 10.1080/01926230500351392. Toxicol Pathol. 2005. PMID: 16263697
Genotoxicity of hormonal steroids.
Joosten HF, van Acker FA, van den Dobbelsteen DJ, Horbach GJ, Krajnc EI. Joosten HF, et al. Among authors: van den dobbelsteen dj. Toxicol Lett. 2004 Jun 15;151(1):113-34. doi: 10.1016/j.toxlet.2004.01.018. Toxicol Lett. 2004. PMID: 15177647 Review.
17 results